Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities
|
01.12.2021 |
Hassanzadeh A.
Rahman H.S.
Markov A.
Endjun J.J.
Zekiy A.O.
Chartrand M.S.
Beheshtkhoo N.
Kouhbanani M.A.J.
Marofi F.
Nikoo M.
Jarahian M.
|
Stem Cell Research and Therapy |
10.1186/s13287-021-02378-7 |
0 |
Ссылка
Recently, mesenchymal stem/stromal cells (MSCs) and their widespread biomedical applications have attracted great consideration from the scientific community around the world. However, reports have shown that the main populations of the transplanted MSCs are trapped in the liver, spleen, and lung upon administration, highlighting the importance of the development of cell-free therapies. Concerning rising evidence suggesting that the beneficial effects of MSC therapy are closely linked to MSC-released components, predominantly MSC-derived exosomes, the development of an MSC-based cell-free approach is of paramount importance. The exosomes are nano-sized (30–100 nm) lipid bilayer membrane vesicles, which are typically released by MSCs and are found in different body fluids. They include various bioactive molecules, such as messenger RNA (mRNA), microRNAs, proteins, and bioactive lipids, thus showing pronounced therapeutic competence for tissues recovery through the maintenance of their endogenous stem cells, the enhancement of regenerative phenotypic traits, inhibition of apoptosis concomitant with immune modulation, and stimulation of the angiogenesis. Conversely, the specific roles of MSC exosomes in the treatment of various tumors remain challenging. The development and clinical application of novel MSC-based cell-free strategies can be supported by better understanding their mechanisms, classifying the subpopulation of exosomes, enhancing the conditions of cell culture and isolation, and increasing the production of exosomes along with engineering exosomes to deliver drugs and therapeutic molecules to the target sites. In the current review, we deliver a brief overview of MSC-derived exosome biogenesis, composition, and isolation methods and discuss recent investigation regarding the therapeutic potential of MSC exosomes in regenerative medicine accompanied by their double-edged sword role in cancer.
Читать
тезис
|
A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine
|
01.12.2021 |
Moghadasi S.
Elveny M.
Rahman H.S.
Suksatan W.
Jalil A.T.
Abdelbasset W.K.
Yumashev A.V.
Shariatzadeh S.
Motavalli R.
Behzad F.
Marofi F.
Hassanzadeh A.
Pathak Y.
Jarahian M.
|
Journal of Translational Medicine |
10.1186/s12967-021-02980-6 |
0 |
Ссылка
Recently, mesenchymal stem/stromal cells (MSCs) due to their pro-angiogenic, anti-apoptotic, and immunoregulatory competencies along with fewer ethical issues are presented as a rational strategy for regenerative medicine. Current reports have signified that the pleiotropic effects of MSCs are not related to their differentiation potentials, but rather are exerted through the release of soluble paracrine molecules. Being nano-sized, non-toxic, biocompatible, barely immunogenic, and owning targeting capability and organotropism, exosomes are considered nanocarriers for their possible use in diagnosis and therapy. Exosomes convey functional molecules such as long non-coding RNAs (lncRNAs) and micro-RNAs (miRNAs), proteins (e.g., chemokine and cytokine), and lipids from MSCs to the target cells. They participate in intercellular interaction procedures and enable the repair of damaged or diseased tissues and organs. Findings have evidenced that exosomes alone are liable for the beneficial influences of MSCs in a myriad of experimental models, suggesting that MSC- exosomes can be utilized to establish a novel cell-free therapeutic strategy for the treatment of varied human disorders, encompassing myocardial infarction (MI), CNS-related disorders, musculoskeletal disorders (e.g. arthritis), kidney diseases, liver diseases, lung diseases, as well as cutaneous wounds. Importantly, compared with MSCs, MSC- exosomes serve more steady entities and reduced safety risks concerning the injection of live cells, such as microvasculature occlusion risk. In the current review, we will discuss the therapeutic potential of MSC- exosomes as an innovative approach in the context of regenerative medicine and highlight the recent knowledge on MSC- exosomes in translational medicine, focusing on in vivo researches.
Читать
тезис
|
A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine
|
01.12.2021 |
Moghadasi S.
Elveny M.
Rahman H.S.
Suksatan W.
Jalil A.T.
Abdelbasset W.K.
Yumashev A.V.
Shariatzadeh S.
Motavalli R.
Behzad F.
Marofi F.
Hassanzadeh A.
Pathak Y.
Jarahian M.
|
Journal of Translational Medicine |
10.1186/s12967-021-02980-6 |
0 |
Ссылка
Recently, mesenchymal stem/stromal cells (MSCs) due to their pro-angiogenic, anti-apoptotic, and immunoregulatory competencies along with fewer ethical issues are presented as a rational strategy for regenerative medicine. Current reports have signified that the pleiotropic effects of MSCs are not related to their differentiation potentials, but rather are exerted through the release of soluble paracrine molecules. Being nano-sized, non-toxic, biocompatible, barely immunogenic, and owning targeting capability and organotropism, exosomes are considered nanocarriers for their possible use in diagnosis and therapy. Exosomes convey functional molecules such as long non-coding RNAs (lncRNAs) and micro-RNAs (miRNAs), proteins (e.g., chemokine and cytokine), and lipids from MSCs to the target cells. They participate in intercellular interaction procedures and enable the repair of damaged or diseased tissues and organs. Findings have evidenced that exosomes alone are liable for the beneficial influences of MSCs in a myriad of experimental models, suggesting that MSC- exosomes can be utilized to establish a novel cell-free therapeutic strategy for the treatment of varied human disorders, encompassing myocardial infarction (MI), CNS-related disorders, musculoskeletal disorders (e.g. arthritis), kidney diseases, liver diseases, lung diseases, as well as cutaneous wounds. Importantly, compared with MSCs, MSC- exosomes serve more steady entities and reduced safety risks concerning the injection of live cells, such as microvasculature occlusion risk. In the current review, we will discuss the therapeutic potential of MSC- exosomes as an innovative approach in the context of regenerative medicine and highlight the recent knowledge on MSC- exosomes in translational medicine, focusing on in vivo researches.
Читать
тезис
|
Parkinson's disease and pesticides: Are microRNAs the missing link?
|
20.11.2020 |
Aloizou A.M.
Siokas V.
Sapouni E.M.
Sita N.
Liampas I.
Brotis A.G.
Rakitskii V.N.
Burykina T.I.
Aschner M.
Bogdanos D.P.
Tsatsakis A.
Hadjigeorgiou G.M.
Dardiotis E.
|
Science of the Total Environment |
10.1016/j.scitotenv.2020.140591 |
0 |
Ссылка
© 2020 Elsevier B.V. Parkinson's disease (PD) is a common neurodegenerative disorder that leads to significant morbidity and decline in the quality of life. It develops due to loss of dopaminergic neurons in the substantia nigra pars compacta, and among its pathogenic factors oxidative stress plays a critical role in disease progression. Pesticides are a broad class of chemicals widely used in agriculture and households for the protection of crops from insects and fungi. Several of them have been incriminated as risk factors for PD, but the underlying mechanisms have yet to be fully understood. MicroRNAs (miRNAs) are small, non-coding RNA molecules that play an important role in regulating mRNA translation and protein synthesis. miRNA levels have been shown to be affected in several diseases as well. Since the studies on the association between pesticides and PD have yet to reach definitive conclusions, here we review recent evidence on deregulated microRNAs upon pesticide exposure, and attempt to find an overlap between miRNAs deregulated in PD and pesticides, as a missing link between the two, and enhance future research in this direction.
Читать
тезис
|
Data on occurrence of miRNA precursors in the Cucurbita maxima phloem sap
|
01.02.2020 |
Tolstyko E.
Lezzhov A.
Solovieva A.
Solovyev A.
|
Data in Brief |
10.1016/j.dib.2019.105083 |
0 |
Ссылка
© 2019 The Author(s) The phloem sieve elements (SEs), enucleate cells, contain RNAs, which are imported from surrounding tissues and cells, mostly companion cells tightly associated with SEs, and transported via the phloem over the whole plant body. The RNA phloem transport is essential for plant individual development and responses to environmental cues. Recently, we identified primary miRNA (pri-miRNA) sequences in de novo assembled transcriptome of Cucurbita maxima phloem sap and reported 11 most abundant pri-miRNAs [1]. Here, we provide the output of this analysis in complete detail. For the full set of pri-miRNAs identified in the C. maxima phloem sap transcriptome, data on relative abundance are provided along with annotated sequence data.
Читать
тезис
|
Role of miRNA in herpesvirus infections
|
01.01.2018 |
Boichenko M.
Budanova E.
Sergeyev O.
Volchkova E.
Belaya O.
|
Infektsionnye Bolezni |
|
0 |
Ссылка
© 2018, Dynasty Publishing House. All rights reserved. This review analyzes the role of viral miRNAs produced by representatives of the Herpesviridae subfamilies (including Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae) in the development of herpesvirus infection. In all three subfamilies, microRNAs are involved in the regulation of latency, i.e. transition of lytic to latent infection. In CMV and HHV-8, miRNAs play an important role in escaping innate immunity. Moreover, viral miRNAs can be transferred to non-infected cells via exosomes.
Читать
тезис
|
Coding and non-coding: Molecular portrait of GIST and its clinical implication
|
01.01.2018 |
Bure I.
Haller F.
Zaletaev D.
|
Current Molecular Medicine |
|
2 |
Ссылка
© 2018 Bentham Science Publishers. Gastrointestinal stromal tumours are the most common mesenchymal tumours of the gastrointestinal tract. Despite similar mutation pattern of activating mutations in KIT or PDGFRA receptors in 85% of cases, they demonstrate significantly heterogeneous clinical behaviour and pathological characteristics. This heterogeneity opens the question of the role of other factors and mechanisms of regulation in the development of GIST. Additional mutations in downstream effectors of GIST related signalling pathways or aberrant expression of non-coding RNAs may be additional contributing factors, the latter being increasingly recognized in carcinogenesis in general. Recently, a substantial progress has been achieved in understanding the functional roles of lncRNAs in GIST suggesting their potential employment as biomarkers and therapeutic targets in GIST. Moreover, some miRNAs have recently been found to be able to sensitize cells to imatinib, which could be an attractive option to overcome the resistance to the drug, which hampers the efficacy of GIST treatment. Therefore, the advantage can be taken of both coding and non-coding parts of the genome in order to significantly improve prognostication and help find personalized therapy for patients, depending on a subtype of GIST and personal characteristics.
Читать
тезис
|